CS223975B2 - Method of making the virus vaccines of the spring-summer meningoencephtalitide - Google Patents
Method of making the virus vaccines of the spring-summer meningoencephtalitide Download PDFInfo
- Publication number
- CS223975B2 CS223975B2 CS798966A CS896679A CS223975B2 CS 223975 B2 CS223975 B2 CS 223975B2 CS 798966 A CS798966 A CS 798966A CS 896679 A CS896679 A CS 896679A CS 223975 B2 CS223975 B2 CS 223975B2
- Authority
- CS
- Czechoslovakia
- Prior art keywords
- virus
- fractions
- specific gravity
- suspension
- gradient
- Prior art date
Links
- 241000700605 Viruses Species 0.000 title claims abstract description 41
- 229960005486 vaccine Drugs 0.000 title claims abstract description 16
- 238000004519 manufacturing process Methods 0.000 title claims description 4
- 239000000725 suspension Substances 0.000 claims abstract description 25
- 206010014599 encephalitis Diseases 0.000 claims abstract description 9
- 201000011475 meningoencephalitis Diseases 0.000 claims abstract description 9
- 239000002245 particle Substances 0.000 claims abstract description 9
- 238000004062 sedimentation Methods 0.000 claims abstract description 9
- 241000271566 Aves Species 0.000 claims abstract description 3
- 238000012258 culturing Methods 0.000 claims abstract description 3
- 238000000034 method Methods 0.000 claims description 24
- 230000005484 gravity Effects 0.000 claims description 16
- 229930006000 Sucrose Natural products 0.000 claims description 12
- 239000005720 sucrose Substances 0.000 claims description 12
- WSFSSNUMVMOOMR-UHFFFAOYSA-N Formaldehyde Chemical compound O=C WSFSSNUMVMOOMR-UHFFFAOYSA-N 0.000 claims description 11
- 239000000243 solution Substances 0.000 claims description 9
- 230000008033 biological extinction Effects 0.000 claims description 8
- 238000005199 ultracentrifugation Methods 0.000 claims description 8
- 102000008100 Human Serum Albumin Human genes 0.000 claims description 5
- 108091006905 Human Serum Albumin Proteins 0.000 claims description 5
- 210000004027 cell Anatomy 0.000 claims description 5
- 210000002308 embryonic cell Anatomy 0.000 claims description 4
- 229960004854 viral vaccine Drugs 0.000 claims description 4
- 241000287828 Gallus gallus Species 0.000 claims description 3
- 102000007327 Protamines Human genes 0.000 claims description 3
- 108010007568 Protamines Proteins 0.000 claims description 3
- VEZXCJBBBCKRPI-UHFFFAOYSA-N beta-propiolactone Chemical compound O=C1CCO1 VEZXCJBBBCKRPI-UHFFFAOYSA-N 0.000 claims description 3
- 239000007853 buffer solution Substances 0.000 claims description 3
- 230000002779 inactivation Effects 0.000 claims description 3
- 229960000380 propiolactone Drugs 0.000 claims description 3
- 238000000108 ultra-filtration Methods 0.000 claims description 3
- 238000000746 purification Methods 0.000 claims description 2
- 229950008679 protamine sulfate Drugs 0.000 claims 1
- 125000000185 sucrose group Chemical group 0.000 claims 1
- 230000003612 virological effect Effects 0.000 claims 1
- 238000005119 centrifugation Methods 0.000 abstract description 4
- 230000001747 exhibiting effect Effects 0.000 abstract description 2
- 238000002835 absorbance Methods 0.000 abstract 1
- 238000002298 density-gradient ultracentrifugation Methods 0.000 abstract 1
- 230000000415 inactivating effect Effects 0.000 abstract 1
- 210000001161 mammalian embryo Anatomy 0.000 abstract 1
- CZMRCDWAGMRECN-UGDNZRGBSA-N Sucrose Chemical compound O[C@H]1[C@H](O)[C@@H](CO)O[C@@]1(CO)O[C@@H]1[C@H](O)[C@@H](O)[C@H](O)[C@@H](CO)O1 CZMRCDWAGMRECN-UGDNZRGBSA-N 0.000 description 11
- 230000001681 protective effect Effects 0.000 description 6
- 238000002360 preparation method Methods 0.000 description 5
- 238000000703 high-speed centrifugation Methods 0.000 description 4
- 238000010790 dilution Methods 0.000 description 3
- 239000012895 dilution Substances 0.000 description 3
- 238000002255 vaccination Methods 0.000 description 3
- PEDCQBHIVMGVHV-UHFFFAOYSA-N Glycerine Chemical compound OCC(O)CO PEDCQBHIVMGVHV-UHFFFAOYSA-N 0.000 description 2
- 241000282412 Homo Species 0.000 description 2
- QAOWNCQODCNURD-UHFFFAOYSA-L Sulfate Chemical compound [O-]S([O-])(=O)=O QAOWNCQODCNURD-UHFFFAOYSA-L 0.000 description 2
- 239000000427 antigen Substances 0.000 description 2
- 102000036639 antigens Human genes 0.000 description 2
- 108091007433 antigens Proteins 0.000 description 2
- 239000000872 buffer Substances 0.000 description 2
- 239000006285 cell suspension Substances 0.000 description 2
- 239000000356 contaminant Substances 0.000 description 2
- 238000007796 conventional method Methods 0.000 description 2
- 230000003053 immunization Effects 0.000 description 2
- 238000002649 immunization Methods 0.000 description 2
- 208000015181 infectious disease Diseases 0.000 description 2
- 239000008055 phosphate buffer solution Substances 0.000 description 2
- 229940048914 protamine Drugs 0.000 description 2
- 239000013049 sediment Substances 0.000 description 2
- 238000007086 side reaction Methods 0.000 description 2
- 229910021653 sulphate ion Inorganic materials 0.000 description 2
- 238000005303 weighing Methods 0.000 description 2
- 102000004190 Enzymes Human genes 0.000 description 1
- 108090000790 Enzymes Proteins 0.000 description 1
- 206010019233 Headaches Diseases 0.000 description 1
- 102000001554 Hemoglobins Human genes 0.000 description 1
- 108010054147 Hemoglobins Proteins 0.000 description 1
- 241000699666 Mus <mouse, genus> Species 0.000 description 1
- 241000699670 Mus sp. Species 0.000 description 1
- 206010067482 No adverse event Diseases 0.000 description 1
- 208000002193 Pain Diseases 0.000 description 1
- 235000014676 Phragmites communis Nutrition 0.000 description 1
- 206010037660 Pyrexia Diseases 0.000 description 1
- 239000002671 adjuvant Substances 0.000 description 1
- WNROFYMDJYEPJX-UHFFFAOYSA-K aluminium hydroxide Chemical compound [OH-].[OH-].[OH-].[Al+3] WNROFYMDJYEPJX-UHFFFAOYSA-K 0.000 description 1
- 230000000890 antigenic effect Effects 0.000 description 1
- 238000003556 assay Methods 0.000 description 1
- AIYUHDOJVYHVIT-UHFFFAOYSA-M caesium chloride Chemical compound [Cl-].[Cs+] AIYUHDOJVYHVIT-UHFFFAOYSA-M 0.000 description 1
- 238000006243 chemical reaction Methods 0.000 description 1
- 238000009826 distribution Methods 0.000 description 1
- 239000003344 environmental pollutant Substances 0.000 description 1
- 238000002474 experimental method Methods 0.000 description 1
- 239000012634 fragment Substances 0.000 description 1
- 235000011187 glycerol Nutrition 0.000 description 1
- 231100000869 headache Toxicity 0.000 description 1
- 238000012872 hydroxylapatite chromatography Methods 0.000 description 1
- 230000036039 immunity Effects 0.000 description 1
- 238000003018 immunoassay Methods 0.000 description 1
- 230000005847 immunogenicity Effects 0.000 description 1
- 230000002458 infectious effect Effects 0.000 description 1
- 230000005764 inhibitory process Effects 0.000 description 1
- 231100000518 lethal Toxicity 0.000 description 1
- 230000001665 lethal effect Effects 0.000 description 1
- 230000004807 localization Effects 0.000 description 1
- 230000036961 partial effect Effects 0.000 description 1
- 231100000719 pollutant Toxicity 0.000 description 1
- AVTYONGGKAJVTE-OLXYHTOASA-L potassium L-tartrate Chemical compound [K+].[K+].[O-]C(=O)[C@H](O)[C@@H](O)C([O-])=O AVTYONGGKAJVTE-OLXYHTOASA-L 0.000 description 1
- 229940111695 potassium tartrate Drugs 0.000 description 1
- 239000001472 potassium tartrate Substances 0.000 description 1
- 235000011005 potassium tartrates Nutrition 0.000 description 1
- 238000001556 precipitation Methods 0.000 description 1
- 102000004169 proteins and genes Human genes 0.000 description 1
- 108090000623 proteins and genes Proteins 0.000 description 1
- 230000009257 reactivity Effects 0.000 description 1
- 230000002829 reductive effect Effects 0.000 description 1
- 230000002441 reversible effect Effects 0.000 description 1
- 208000024891 symptom Diseases 0.000 description 1
- 230000009885 systemic effect Effects 0.000 description 1
- 239000003104 tissue culture media Substances 0.000 description 1
- 241000712461 unidentified influenza virus Species 0.000 description 1
- 210000001215 vagina Anatomy 0.000 description 1
Classifications
-
- B—PERFORMING OPERATIONS; TRANSPORTING
- B28—WORKING CEMENT, CLAY, OR STONE
- B28D—WORKING STONE OR STONE-LIKE MATERIALS
- B28D1/00—Working stone or stone-like materials, e.g. brick, concrete or glass, not provided for elsewhere; Machines, devices, tools therefor
- B28D1/02—Working stone or stone-like materials, e.g. brick, concrete or glass, not provided for elsewhere; Machines, devices, tools therefor by sawing
- B28D1/06—Working stone or stone-like materials, e.g. brick, concrete or glass, not provided for elsewhere; Machines, devices, tools therefor by sawing with reciprocating saw-blades
- B28D1/068—Components, e.g. guiding means, vibrations damping means, frames, driving means, suspension
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K39/12—Viral antigens
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K2039/51—Medicinal preparations containing antigens or antibodies comprising whole cells, viruses or DNA/RNA
- A61K2039/525—Virus
- A61K2039/5252—Virus inactivated (killed)
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N2770/00—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA ssRNA viruses positive-sense
- C12N2770/00011—Details
- C12N2770/24011—Flaviviridae
- C12N2770/24111—Flavivirus, e.g. yellow fever virus, dengue, JEV
- C12N2770/24134—Use of virus or viral component as vaccine, e.g. live-attenuated or inactivated virus, VLP, viral protein
-
- Y—GENERAL TAGGING OF NEW TECHNOLOGICAL DEVELOPMENTS; GENERAL TAGGING OF CROSS-SECTIONAL TECHNOLOGIES SPANNING OVER SEVERAL SECTIONS OF THE IPC; TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
- Y02—TECHNOLOGIES OR APPLICATIONS FOR MITIGATION OR ADAPTATION AGAINST CLIMATE CHANGE
- Y02A—TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE
- Y02A50/00—TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE in human health protection, e.g. against extreme weather
- Y02A50/30—Against vector-borne diseases, e.g. mosquito-borne, fly-borne, tick-borne or waterborne diseases whose impact is exacerbated by climate change
Landscapes
- Life Sciences & Earth Sciences (AREA)
- Health & Medical Sciences (AREA)
- Engineering & Computer Science (AREA)
- Medicinal Chemistry (AREA)
- Mycology (AREA)
- Mechanical Engineering (AREA)
- Chemical & Material Sciences (AREA)
- Immunology (AREA)
- Mining & Mineral Resources (AREA)
- Microbiology (AREA)
- Virology (AREA)
- Pharmacology & Pharmacy (AREA)
- Epidemiology (AREA)
- Animal Behavior & Ethology (AREA)
- General Health & Medical Sciences (AREA)
- Public Health (AREA)
- Veterinary Medicine (AREA)
- Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
- Micro-Organisms Or Cultivation Processes Thereof (AREA)
Applications Claiming Priority (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| AT922078A AT358167B (de) | 1978-12-22 | 1978-12-22 | Verfahren zur herstellung von fruehsommer- -meningoenzephalitis-virus (fsme-virus)- -vakzinen |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| CS223975B2 true CS223975B2 (en) | 1983-11-25 |
Family
ID=3612255
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| CS798966A CS223975B2 (en) | 1978-12-22 | 1979-12-18 | Method of making the virus vaccines of the spring-summer meningoencephtalitide |
Country Status (11)
| Country | Link |
|---|---|
| AT (1) | AT358167B (de) |
| BE (1) | BE880732A (de) |
| CH (1) | CH644271A5 (de) |
| CS (1) | CS223975B2 (de) |
| DE (1) | DE2950004C2 (de) |
| FR (1) | FR2444466A1 (de) |
| GB (1) | GB2038179B (de) |
| IT (1) | IT1126676B (de) |
| SE (1) | SE447789B (de) |
| SU (2) | SU1003738A3 (de) |
| YU (1) | YU42204B (de) |
Families Citing this family (7)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| AT384363B (de) * | 1982-10-05 | 1987-11-10 | Immuno Ag | Verfahren zur verwendung von antigenreaktiven peptiden zur herstellung von gegen fsme-virusinfektionen wirksamen vakzinen |
| AT385203B (de) * | 1985-04-26 | 1988-03-10 | Immuno Ag | Verfahren zur herstellung einer fruehsommermeningoenzephalitis-virus (fsme-virus)-vakzine |
| AT393356B (de) * | 1989-12-22 | 1991-10-10 | Immuno Ag | Verfahren zur herstellung von fsme-virus-antigen |
| US5719051A (en) * | 1989-12-22 | 1998-02-17 | Immuno Aktiengesellschaft | Perfusion system and a method for the large scale production of virus or virus antigen |
| AT393277B (de) * | 1990-01-04 | 1991-09-25 | Immuno Ag | Verfahren zur herstellung von fruehsommer- meningoenzephalitis-virus (fsme-virus)-antigen |
| IT1305405B1 (it) * | 1998-02-18 | 2001-05-04 | Augusto Cappelli | Telaio di taglio per la segagione di blocchi di pietra, roccia,granito, marmo, o simili. |
| RU2203089C2 (ru) * | 2001-06-28 | 2003-04-27 | Федеральное Государственное унитарное предприятие научно-производственное объединение "Вирион" | Способ получения вакцины клещевого энцефалита |
Family Cites Families (2)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| GB1152626A (en) * | 1967-07-07 | 1969-05-21 | Merck & Co Inc | Rubella Vaccine |
| GB1453035A (en) * | 1972-12-21 | 1976-10-20 | Secr Defence | Virus vaccine production |
-
1978
- 1978-12-22 AT AT922078A patent/AT358167B/de not_active IP Right Cessation
-
1979
- 1979-12-06 SE SE7910054A patent/SE447789B/sv not_active IP Right Cessation
- 1979-12-12 DE DE2950004A patent/DE2950004C2/de not_active Expired - Lifetime
- 1979-12-12 GB GB7942857A patent/GB2038179B/en not_active Expired
- 1979-12-18 CS CS798966A patent/CS223975B2/cs unknown
- 1979-12-18 CH CH1122379A patent/CH644271A5/de not_active IP Right Cessation
- 1979-12-19 YU YU311779A patent/YU42204B/xx unknown
- 1979-12-19 BE BE0/198645A patent/BE880732A/fr not_active IP Right Cessation
- 1979-12-20 FR FR7931278A patent/FR2444466A1/fr active Granted
- 1979-12-21 SU SU792854825A patent/SU1003738A3/ru active
- 1979-12-21 SU SU792854825K patent/SU1318149A3/ru active
- 1979-12-21 IT IT2834179A patent/IT1126676B/it active
Also Published As
| Publication number | Publication date |
|---|---|
| SU1318149A3 (ru) | 1987-06-15 |
| YU311779A (en) | 1983-10-31 |
| IT1126676B (it) | 1986-05-21 |
| ATA922078A (de) | 1980-01-15 |
| DE2950004C2 (de) | 1991-04-18 |
| CH644271A5 (de) | 1984-07-31 |
| GB2038179B (en) | 1983-02-16 |
| FR2444466A1 (fr) | 1980-07-18 |
| IT7928341A0 (it) | 1979-12-21 |
| DE2950004A1 (de) | 1980-07-03 |
| FR2444466B1 (de) | 1983-07-08 |
| SU1003738A3 (ru) | 1983-03-07 |
| YU42204B (en) | 1988-06-30 |
| SE7910054L (sv) | 1980-06-23 |
| GB2038179A (en) | 1980-07-23 |
| SE447789B (sv) | 1986-12-15 |
| BE880732A (fr) | 1980-04-16 |
| AT358167B (de) | 1980-08-25 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| CA2197683C (en) | Method for preparing an influenza virus, antigens obtained and applications thereof | |
| Woodroofe et al. | Serological relationships within the poxvirus group: an antigen common to all members of the group | |
| JP5264843B2 (ja) | 細胞培養におけるインフルエンザウイルスの複製の方法、および本方法によって入手可能なインフルエンザウイルス | |
| Campbell et al. | Fowl plague virus from man | |
| Schaffer et al. | Purification and properties of poliovirus | |
| US3962421A (en) | Method for the disruption of lipid-containing viruses | |
| EP0048201B1 (de) | Impfstoff auf der Basis einer Fraktion des Herpes Simplex Typ I-Virus und Verfahren zu dessen Herstellung | |
| JP2009225809A (ja) | 日本脳炎ウイルス群感染症に対する不活化ワクチンのための増強免疫原およびその製造方法 | |
| Beveridge et al. | MUMPS 2. VIRUS HAEMAGGLUTINATION AND SEROLOGICAL REACTIONS. | |
| CS223975B2 (en) | Method of making the virus vaccines of the spring-summer meningoencephtalitide | |
| JPH05260962A (ja) | ニワトリ貧血因子ワクチン | |
| Le Cam et al. | Adjuvants for influenza vaccine | |
| Åkerblom et al. | Formation and characterization of FeLV ISCOMs | |
| NL8005577A (nl) | Werkwijze voor het bereiden van een vaccin. | |
| US3769415A (en) | Method of preparing a killed vaccine for oral use | |
| Tzianabos et al. | Origin and structure of the group-specific, complement-fixing antigen of Rickettsia rickettsii | |
| AU649728B2 (en) | Vaccines against equine herpesviruses and the preparation thereof | |
| Schneider et al. | Purification of rabies virus from tissue culture | |
| Ananthanarayan | The fabric of virus elementary bodies | |
| Buckley et al. | Production of hemagglutinin by dengue virus in HeLa cells | |
| KR20210065952A (ko) | 불활화 전입자 인플루엔자 백신 및 그 조제법 | |
| CA1163556A (en) | Vaccine for infectious bovine rhinotracheitis | |
| Brady et al. | An adsorbed surface-antigen influenza vaccine and its serological activity in volunteers | |
| Perlowagora et al. | The Complement Fixation Test in Yellow Fever Epidemiology: The Use of Globulin Antigen in Immunity Surveys | |
| JPS58222034A (ja) | 抗ｄｎａウイルスワクチン及びその調整方法 |